Observational studyClinical cancer research : an official journal of the American Association for Cancer Research2026

Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT).

Ferdinandos Skoulidis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.